(S)-(-)-Anatabine
Based on 1 publication(s) in Google Scholar
(S)-(-)-Anatabine is an NFκB/BACE-1 inhibitor with blood-brain barrier penetration. (S)-(-)-Anatabine inhibits NFκB activation via phosphorylation of its p65 subunit. (S)-(-)-Anatabine inhibits BACE-1 transcription and reduces BACE-1 protein levels. (S)-(-)-Anatabine lowers production of Aβ1-40 and Aβ1-42 by reducing β-cleavage of amyloid precursor protein without affecting α-cleavage. (S)-(-)-Anatabine can be used for the research of Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 581-49-7
- Formula: C10H12N2
- Molecular Weight:160.22
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (S)-(-)-Anatabine
More
Biological Activity
|
NF-κB |
BACE1 |
(S)-(-)-Anatabine (24 h) dose-dependently reduces Aβ1-40 and Aβ1-42 production with an IC50 of 640 μg/mL[1].
(S)-(-)-Anatabine (200-800 μg/mL; 3 h) dose-dependently inhibits TNFα-induced NFκB activation in HEK293 NFκB luciferase reporter cells[1].
(S)-(-)-Anatabine (600 μg/mL; 24 h) inhibits basal p65 NFκB phosphorylation in 7W CHO cells overexpressing human APP, and inhibits TNFα-induced p65 NFκB phosphorylation in HEK293 and SHSY-5Y cells[1].
(S)-(-)-Anatabine (500-1000 μg/mL; 30 min) fully inhibits TNFα-induced BACE-1 transcription in human neuronal-like SHSY-5Y cells[1].
(S)-(-)-Anatabine (5-1000 μg/mL; 24 h) dose-dependently reduces BACE-1 protein levels in human neuronal-like SHSY-5Y cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:7W CHO cells overexpressing human APP, HEK293 cells, human neuronal-like SHSY-5Y cells
-
Concentration:600 μg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced basal p65 NFκB phosphorylation relative to controls in 7W CHO cells.
Significantly reduced TNFα-induced p65 NFκB phosphorylation relative to TNFα-only treatment in HEK293 and SHSY-5Y cells.
-
Cell Line:human neuronal-like SHSY-5Y cells
-
Concentration:500 μg/mL; 1000 μg/mL
-
Incubation Time:30 min
-
Result:Fully prevented the TNFα-induced increase in BACE-1 mRNA levels at both 500 μg/mL and 1000 μg/mL.
Showed no significant difference in BACE-1 mRNA levels between control cells and cells treated with TNFα + anatabine.
-
Cell Line:human neuronal-like SHSY-5Y cells
-
Concentration:5 μg/mL; 20 μg/mL; 50 μg/mL; 100 μg/mL; 200 μg/mL; 800 μg/mL; 1000 μg/mL
-
Incubation Time:24 h
-
Result:Reduced BACE-1 protein levels dose-dependently.
Caused statistically significant reductions in BACE-1 protein levels relative to controls at all doses higher than 50 μg/mL.
| Species | Dose | Route | AUC0-∞ (Brain) | Cmax (Brain) | AUC0-∞ (Plasma) | Cmax |
|---|---|---|---|---|---|---|
| Mice[1] | 2 mg/kg | i.v. | 172384 min·ng/mL | 5194.4 ng/mL | 49968 min·ng/mL | 1501.7 ng/mL |
and the maximal concentration (Cmax) achieving approximately 3.5 times greater in the brain of B6/SJL F1 mice than in the plasma[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B6/SJL F1 mice (43 week-old)[1]
-
Dosage:2 mg/kg
-
Administration:i.p.; single dose
-
Result:Exhibited AUC of 172384.9 ng·min/mL and 49968 ng·min/mL in the brain and plasma, respectively.
Exhibited Cmax of 5194.4 ng/mL and 1501.7 ng/mL in the brain and plasma, respectively.
Chemical Information
-
CAS No. 581-49-7
-
Molecular Weight 160.22
-
Formula C10H12N2
-
SMILES
[C@@H]1(C2=CC=CN=C2)CC=CCN1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cardiovasc Toxicol
Chronic Anatabine Administration Attenuates Cardiovascular Activity by Targeting NF-κB/NLRP3/Caspase-1-Dependent Pyroptosis and Oxidative Stress in Paraventricular Nucleus of Hypertensive Rat. [Abstract]2025 Sep;25(9):1352-1368. PMID: 40690148
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(S)-(-)-Anatabine Related Classifications
HY-126047 Related Classifications
Powered by Bioz